June 25, 2026 · Form 4 insider transaction
Martin Samuel Bates bought 93,000 shares of Celldex Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.; 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.